The online version of this article (doi:10.1007/s00705-014-2185-1) contains supplementary material, which is available to authorized users.
X. Rong, R. Xu and H. Xiong contributed equally to the work.
Different hepatitis C virus (HCV) genotypes exhibit differences in disease pathogenesis and progression, as well as disease outcomes and response to therapy. Tracking the change of HCV genotypes in various epidemiological settings is critical for both disease surveillance and the development of improved antiviral treatment. Here, we tracked the changes in the prevalence of the HCV genotypes in China between 2004-2007 and 2008-2011. HCV-RNA-positive sera were collected from volunteer blood donors during the period 2008-2011. The genotypes were determined by phylogenic analysis using the NS5B and E1 sequences. Geographical and demographic distribution patterns related to the HCV genotypes obtained in 2008-2011 were compared with our previous study, which recorded data in the period 2004-2007. Pearson chi-square test and t-test were used to statistically analyze the results. In 2008-2011, HCV subtypes 1b and 6a were detected in 43.8 % (184/420) and 34.3 % (144/420), respectively. The male/female ratio was found to be higher for HCV genotype 6 than for genotypes 1 and 2. When compared with the period of 2004-2007, although no significant difference was found in gender or age for genotypes 1, 2, 3 and 6, the subtype 6a frequency was significantly increased from 11 % to 26.5 % in the blood donors from outside of Guangdong Province in 2008-2011. A pattern of increase in HCV subtype 6a was found in blood donors outside of Guangdong Province, indicating that HCV subtype 6a has rapidly spread from Guangdong to other regions of China over the past 10 years.
Supplementary material 1 (FAS 240 kb)705_2014_2185_MOESM1_ESM.fas
Supplementary material 2 (FAS 161 kb)705_2014_2185_MOESM2_ESM.fas
Supplemental Figure 1 Phylogenetic tree constructed from (1a) E1 and (1b) NS5B nucleotide sequences. Bootstrap values are shown in the tree root. The scale bar represents 0.05 nucleotide substitutions per site. GZ- means the strains from Guangdong, n-GZ- means the strains from non-Guangdong. (Reference strains are represented in red circles) (PDF 59 kb)
Global Burden of Hepatitis C Working Group (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44(1):20–29
Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973 PubMedCrossRef
Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Farkkila M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G (2013) Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol 48:839–847 PubMedCrossRef
Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y (2013) New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection. J Med Virol 85:1523–1533 PubMedCrossRef
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965 PubMedCrossRef
Casey LC, Lee WM (2013) Hepatitis C virus therapy update. Curr Opin Gastroenterol 29:243–249 PubMed
Maieron A, Metz-Gercek S, Hackl F, Luger C, Ziachehabi A, Strauss R, Schofl R, Mittermayer H (2010) Chronic hepatitis C in Austria, 1992-2006: genotype distribution and demographic factors. Euro Surveill 15:19492 PubMed
Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustiere C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P (2002) Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 9:62–70 PubMedCrossRef
Ding X, Gu H, Zhong ZH, Zilong X, Tran HT, Iwaki Y, Li TC, Sata T, Abe K (2003) Molecular epidemiology of hepatitis viruses and genotypic distribution of hepatitis B and C viruses in Harbin, China. Jpn J Infect Dis 56:19–22 PubMed
Fu Y, Xia W, Wang Y, Tian L, Pybus OG, Lu L, Nelson K (2010) The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion 50:1505–1511 PubMedCentralPubMedCrossRef
Fu Y, Qin W, Cao H, Xu R, Tan Y, Lu T, Wang H, Tong W, Rong X, Li G, Yuan M, Li C, Abe K, Lu L, Chen G (2012) HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China: phylogeographic analyses. PLoS One 7:e28006 PubMedCentralPubMedCrossRef
van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M (2009) Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136:1609–1617 PubMedCrossRef
- Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011
- Springer Vienna
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II